BioSpace News Archive

Drug Development

BrainStorm Cell Therapeutics Presents New Analyses from NurOwn’s Phase 3 ALS Trial at the 21st Annual NEALS Meeting

BrainStorm Cell Therapeutics Inc. announced the presentation of a poster with new analyses from NurOwn’s placebo-controlled Phase 3 amyotrophic lateral sclerosis trial that account for limitations in the Revised ALS Functional Rating Scale and provide evidence of a clinically meaningful treatment effect.

November 7, 2022
·
10 min read
Business

Haemonetics 2nd Quarter Fiscal Year 2023 Earnings Release Available on Investor Relations Website

Haemonetics Corporation announced that financial results for its second quarter fiscal 2023, which ended October 1, 2022, are available on its Investor Relations website.

November 7, 2022
·
2 min read
FDA

Anavex Announces U.S. FDA Orphan Drug Designation to ANAVEX®2-73 (blarcamesine) for the Treatment of Fragile X Syndrome

Anavex Life Sciences Corp. today reports the U.S. Food and Drug Administration’s (FDA) has granted Orphan Drug Designation (ODD) to ANAVEX®2-73 (blarcamesine) for the treatment of Fragile X syndrome.

November 7, 2022
·
5 min read
BioForest

Athira Pharma to Present Preclinical Data Highlighting Therapeutic Potential of HGF/MET Platform in Neurodegenerative Disorders at Neuroscience 2022 Conference

Athira Pharma, Inc. today announced that it will be presenting preclinical data demonstrating the therapeutic potential of enhancing the HGF/MET neurotrophic system at Neuroscience 2022.

November 7, 2022
·
5 min read
Drug Development

Kamada Provides Update on Recent Progress Achieved in Ongoing Pivotal Phase 3 Clinical Trial of Inhaled AAT

Kamada today provided an update on recent progress achieved in its ongoing pivotal Phase 3 InnovAATe clinical trial evaluating the safety and efficacy of the Company’s proprietary inhaled Alpha-1 Antitrypsin (AAT) therapy for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).

November 7, 2022
·
6 min read
Business

Tonix Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Highlights

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced financial results for the third quarter ended September 30, 2022, and provided an overview of recent operational highlights.

November 7, 2022
·
15 min read
Deals

Bio-Path Holdings, Inc. Announces $2.0 Million Registered Direct Offering and Concurrent Private Placement

Bio-Path Holdings, Inc., today announced that it has entered into a definitive agreement with certain institutional investors for the issuance and sale of 800,000 shares of its common stock (or common stock equivalents) for a price of $2.50 per share.

November 7, 2022
·
5 min read
Chemomab Presents Preclinical Data at AASLD The Liver Meeting® 2022 Highlighting Key Role of CCL24 in Pathophysiology of Primary Sclerosing Cholangitis

Chemomab Therapeutics, Ltd. today announced a poster presentation at The Liver Meeting® 2022, hosted by the American Association for the Study of Liver Diseases (AASLD), being held in Washington, D.C. November 4-8, 2022.

November 7, 2022
·
6 min read
Pharm Country

Synchrony Airway Clearance System Prototype Helps Save Patient’s Life

Synchrony Medical ‘s LibAirty, helped save the life of a 38-year-old patient who traveled from Israel to the U.S.

November 7, 2022
·
3 min read
ADC Therapeutics to Participate in the Jefferies 2022 London Healthcare Conference

ADC Therapeutics SA announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 15th at 9:45 a.m. GMT.

November 7, 2022
·
1 min read